The clinical efficacy of Dermacell AWM is supported by a growing number of peer-reviewed, clinical publications. The clinical efficacy of competing grafts has also been shown in the literature. However, information on cost-effectiveness of those grafts has been lacking. Using the most recent cost data, a meta-analysis determined that higher cost does not necessarily correlate with higher rates of healing. Dermacell AWM is an option that is not only clinically efficacious, but cost-effective too.

Macrophage phenotypes correspond with remodeling outcomes of various acellular dermal matrices

Beyond peer-reviewed publications, there are a number of case studies supporting the use of Dermacell AWM for treating hard-to-heal wounds. From diabetic foot ulcers, to trauma, and burn reconstruction, Dermacell AWM is effective for complete resolution with one application.

Dermacell AWM is a technologically advanced human acellular dermal matrix that is decellularized using Matracell^®, a proprietary, patented, and validated processing technology. Matracell removes a minimum of 97% of donor DNA¹, allowing for rapid cellular infiltration and re-vascularization. Dermacell AWM is terminally sterilized, ready to use without refrigeration or re-hydration.

The Ross Procedure: Advanced Surgical Techniques for a Successful Outcome

Clinical Reports using VertiGraft in Cervical ACDF

Abla A, El Kadi H, Bost J, Maroon J, and Wert M. Allograft Composite Cortical and Cancellous Bone Graft for Anterior Cerival Fusion.Contemporary Neurosurgery: A Biweekly Publication for Clinical Neurosurgical Continuing Medical Education. 2005;27(8):1-6.

There is a growing body of clinical evidence supporting ViviGen and ViviGen Formable cellular bone matrix, including recent data that shows effective multi-level fusion even in challenging cases.